

Jornay^{PM}

methylphenidate HCl 
extended-release capsules

20mg 40mg 60mg 80mg 100mg

Wake Ready. Stay Ready.



Dosing & Optimization Guide

Due to its delayed-release/extended-release formulation, JORNAY PM[®] is taken in the evening to deliver therapeutic levels by morning and support readiness upon awakening that lasts throughout the day and into the late afternoon/evening.^{1,2}

The only long-acting methylphenidate dosed at night so patients can wake ready and stay ready¹⁻³



20 mg



40 mg



60 mg



80 mg



100 mg

Capsules shown are not the actual size.

INDICATION

JORNAY PM (methylphenidate HCl extended-release capsules) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Limitations of Use: The use of JORNAY PM is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: ABUSE, MISUSE, AND ADDICTION

JORNAY PM has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including JORNAY PM, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing JORNAY PM, assess each patient's risk for abuse, misuse, and addiction.

Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout JORNAY PM treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse and addiction.

Please see additional [Important Safety Information](#) throughout and accompanying Full Prescribing Information including Boxed Warning or at JORNAYPM-PRO.com/pi

IMPORTANT SAFETY INFORMATION

BOXED WARNING: ABUSE, MISUSE, AND ADDICTION

JORNAY PM has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including JORNAY PM, can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing JORNAY PM, assess each patient's risk for abuse, misuse, and addiction.

Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout JORNAY PM treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse and addiction.

CONTRAINDICATIONS

- Known hypersensitivity to methylphenidate or other components of JORNAY PM. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate products.
- Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days because of the risk of hypertensive crisis.

WARNINGS AND PRECAUTIONS

JORNAY PM can cause serious adverse reactions and patients should be monitored for the following:

- *Risks to Patients with Serious Cardiac Disease:* Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.
- *Increased Blood Pressure and Heart Rate.*
- *Psychiatric Adverse Reactions:* Including exacerbation of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder, induction of a manic episode in patients with bipolar disorder, and new psychotic or manic symptoms. Prior to initiating treatment, screen patients for risk factors for psychiatric adverse reactions. If such symptoms occur, consider discontinuing JORNAY PM.
- *Priapism:* Patients should seek immediate medical attention.
- *Peripheral Vasculopathy, including Raynaud's Phenomenon:* Observe patients for digital changes during treatment.

Jornay^{PM}
methylphenidate HCl 
extended-release capsules
20mg 40mg 60mg 80mg 100mg

WARNINGS AND PRECAUTIONS (cont'd)

- *Weight Loss and Long-Term Suppression of Growth in Pediatric Patients:* Monitor height and weight. JORNAY PM is not approved for use and is not recommended in pediatric patients below 6 years of age.
- *Increased Intraocular Pressure (IOP) and Glaucoma:* Patients at risk for acute angle closure glaucoma should be evaluated by an ophthalmologist. Closely monitor patients with a history of abnormally increased IOP or open angle glaucoma.
- *Onset or Exacerbation of Motor and Verbal Tics and Worsening of Tourette's Syndrome.*

ADVERSE REACTIONS

- The most common ($\geq 5\%$ and twice the rate of placebo) adverse reactions with methylphenidate are decreased appetite, insomnia, nausea, vomiting, dyspepsia, abdominal pain, decreased weight, anxiety, dizziness, irritability, affect lability, tachycardia, and increased blood pressure.
- Additional adverse reactions ($\geq 5\%$ and twice the rate of placebo) in JORNAY PM-treated pediatric patients 6 to 12 years are headache, psychomotor hyperactivity, and mood swings.


DRUG INTERACTIONS

- Antihypertensive drugs: Monitor blood pressure; adjust dosage of antihypertensive drug as needed.

To report SUSPECTED ADVERSE REACTIONS, contact Collegium Pharmaceutical, Inc. at 1-855-331-5615 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Please see accompanying Full Prescribing Information including Boxed Warning or at JORNAYPM-PRO.com/pi

References: 1. JORNAY PM® [package insert]. Ironshore Pharmaceuticals & Development, Inc.
2. Childress AC, Cutler AJ, Marraffino A, et al. A randomized, double-blind, placebo-controlled study of HLD200, a delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder: an evaluation of safety and efficacy throughout the day and across settings. *J Child Adolesc Psychopharmacol.* 2020;30(1):2-14. doi:10.1089/cap.2019.0070
3. Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol.* 2017;27(6):474-482. doi:10.1089/cap.2017.0084
4. Data on File. Collegium Pharmaceutical. 2025.



Once-daily JORNAY PM offers multiple dosage options for dose optimization¹

>75% of patients were optimized at 60 mg and above⁴



% of patients by optimized dose at the end of the dose-optimization phase of Study 1⁴
Capsules shown are not the actual size.

- JORNAY PM[®] is a once-daily capsule that should be **taken in the evening**. Do not take JORNAY PM in the morning¹
- Adjust dosing time between **6:30 PM and 9:30 PM**, as needed. In clinical trials, the most common dosing time was 8 PM¹
- The **recommended starting dose for patients 6 years and older is 20 mg**¹
- Dose may be **titrated weekly in 20-mg/day increments** up to a maximum daily dose of 100 mg/day^{1*}
- Following the dose-optimization phase of pivotal Study 1, the **mean final dose was 66.2 mg/day**^{1,2}
- Do not substitute JORNAY PM for other MPH products on a mg-per-mg basis. When switching from another MPH formulation, discontinue the previous treatment and initiate JORNAY PM according to the titration schedule
- If the patient cannot swallow the capsule whole, it may be opened and the **entire contents** sprinkled onto applesauce (to be consumed immediately and entirely without chewing)¹

*A daily dose above 100 mg has not been studied or recommended.
MPH=methylphenidate.

IMPORTANT SAFETY INFORMATION (cont'd) CONTRAINDICATIONS

- Known hypersensitivity to methylphenidate or other components of JORNAY PM. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate products.

Please see additional **Important Safety Information** throughout and accompanying **Full Prescribing Information** including **Boxed Warning** or at JORNAYPM-PRO.com/pi

JORNAY PM[®] is a registered trademark of Ironshore Pharmaceuticals Inc., a wholly-owned subsidiary of Collegium Pharmaceutical, Inc. Collegium Pharmaceutical and the Collegium Pharmaceutical logo are registered trademarks of Collegium Pharmaceutical, Inc.
© 2025 Collegium Pharmaceutical, Inc. All rights reserved.
PP-JNY-US-0476 11/25

Scan or click the QR code



or learn more at
JORNAYPM-pro.com/savings